^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Uveal Melanoma
    Drug:Koselugo (selumetinib) (MEK inhibitor) +
    AZD8055 (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

    Excerpt:
    In both GNAQ and BRAF cells, the AZD8055/selumetinib combination at different dose combinations consistently reduced cell viability by more than 50% (“fractional activity” (Fa) >0.5) in a synergistic manner (combination index (CI) values <1) (Figure 1A). 
    DOI:
    10.1371/journal.pone.0040439